Literature DB >> 16321813

Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition.

Jane L Liesveld1, Karen E Rosell, Chaohui Lu, Jeremy Bechelli, Gordon Phillips, Jeffrey E Lancet, Camille N Abboud.   

Abstract

How leukemia progenitors interact with marrow microenvironment components is poorly understood. In this work, the effects of endothelial coculture on acute myelogenous leukemia (AML) blast survival is examined as are the effects of endothelial coculture on the impact of a cytotoxic agent such as cytarabine. Similar to marrow stromal cells, endothelial cells are able to increase survival and proliferation of AML blasts and to partially protect against cytarabine effects. The proteasome inhibitor, bortezomib, has inhibitory effects in multiple myeloma in part through effects on marrow stromal cells. Bortezomib has been found to inhibit AML blast survival. Such inhibition is less, however, in the presence of endothelial monolayers. Furthermore, AML blast transmigration through human umbilical vein endothelial cells is inhibited by bortezomib. These studies demonstrate that AML is subject to influence of endothelial cells and of agents such as bortezomib which have potential impact on AML interaction with the microenvironmental niche.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16321813     DOI: 10.1080/10245330500233452

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  18 in total

1.  Leukemia regression by vascular disruption and antiangiogenic therapy.

Authors:  Gerard J Madlambayan; Amy M Meacham; Koji Hosaka; Saad Mir; Marda Jorgensen; Edward W Scott; Dietmar W Siemann; Christopher R Cogle
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

Review 2.  Enabling stem cell therapies through synthetic stem cell-niche engineering.

Authors:  Raheem Peerani; Peter W Zandstra
Journal:  J Clin Invest       Date:  2010-01       Impact factor: 14.808

3.  Myeloid malignancies and the microenvironment.

Authors:  Claudia Korn; Simón Méndez-Ferrer
Journal:  Blood       Date:  2016-11-15       Impact factor: 22.113

4.  Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.

Authors:  Jane L Liesveld; Karen E Rosell; Jeremy Bechelli; Chaohui Lu; Patti Messina; Deborah Mulford; J J Ifthikharuddin; Craig T Jordan; Gordon L Phillips Ii
Journal:  Cancer Invest       Date:  2011-08       Impact factor: 2.176

5.  Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells.

Authors:  Jane L Liesveld; Jeremy Bechelli; Karen Rosell; Chaohui Lu; Gary Bridger; Gordon Phillips; Camille N Abboud
Journal:  Leuk Res       Date:  2007-04-02       Impact factor: 3.156

Review 6.  Cell intrinsic and extrinsic regulation of leukemia cell metabolism.

Authors:  Yajian Jiang; Daisuke Nakada
Journal:  Int J Hematol       Date:  2016-02-20       Impact factor: 2.490

Review 7.  Acute myelogenous leukemia stem cells: from Bench to Bedside.

Authors:  J Felipe Rico; Duane C Hassane; Monica L Guzman
Journal:  Cancer Lett       Date:  2012-06-17       Impact factor: 8.679

8.  Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

Authors:  Zhihong Zeng; Yue Xi Shi; Ismael J Samudio; Rui-Yu Wang; Xiaoyang Ling; Olga Frolova; Mark Levis; Joshua B Rubin; Robert R Negrin; Elihu H Estey; Sergej Konoplev; Michael Andreeff; Marina Konopleva
Journal:  Blood       Date:  2008-10-27       Impact factor: 22.113

9.  Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.

Authors:  Anil Shanker; Samuel T Pellom; Duafalia F Dudimah; Menaka C Thounaojam; Rachel L de Kluyver; Alan D Brooks; Hideo Yagita; Daniel W McVicar; William J Murphy; Dan L Longo; Thomas J Sayers
Journal:  Cancer Res       Date:  2015-10-22       Impact factor: 12.701

Review 10.  The leukemic stem cell niche: current concepts and therapeutic opportunities.

Authors:  Steven W Lane; David T Scadden; D Gary Gilliland
Journal:  Blood       Date:  2009-04-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.